Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Discovery and Clinical Validation of Circulating microRNAs as Novel Molecular Diagnostics of Hepatitis C Virus-Associated Liver Diseases
EF 2015-16
Résumé
Hepatitis C, which affects approximately 170 million people worldwide, is a chronic liver disease caused by the hepatitis C virus (HCV) which can lead to liver cirrhosis, liver failure, and liver cancer. Given the high cost of treatment and the large number of HCV-infected individuals, identification of predictors of progressive liver disease and treatment outcome may aid in diagnosis and treatment planning on an individual patient basis. It has been shown that human microRNAs(miRNA) are needed to promote and maintain HCV infection. MicroRNAs are small ribonucleic acid (RNA) sequences which bind protein-producing RNA sequences, lowering concentrations of certain proteins in cells. There are many different miRNA sequences that are found in varying concentrations in the body; abnormal concentrations of certain miRNAs can be a symptom of viral disease. MicroRNAs can be packaged and delivered to cells in exosomes, small packaging bodies which are found in body fluids such as plasma. The purpose of this study is to identify exosomal miRNAs that vary in concentration in patients chronically infected with HCV pre-, during and post-treatment at different stages of HCV-associated liver disease progression. Exosomal miRNA from plasma samples from patients with chronic hepatitis C before, during, and at the end of HCV treatment will be isolated, quantified, and identified to determine the concentration of certain miRNA sequences associated with HCV infection. Outcome measures include the relationship between miRNA levels and the patients' stage of liver disease progression, the relationship in miRNA levels before, during and post- treatment, and the relationship in miRNA levels compared to responsiveness to the treatment by measured HCV load.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
350113
Name
Noble Jake W
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Discovery and Clinical Validation of Circulating microRNAs as Novel Molecular Diagnostics of Hepatitis C Virus-Associated Liver Diseases
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarkers; Exosomes; Genomics; Hepatitis C; Hepatitis C Virus; Hepatitis C Virus-Associated Liver Diseases; Microrna; Noninvasive Diagnosis; Quantitative Polymerase Chain Reaction; Reverse Transcription Polymerase Chain Reaction
Abstract
Hepatitis C, which affects approximately 170 million people worldwide, is a chronic liver disease caused by the hepatitis C virus (HCV) which can lead to liver cirrhosis, liver failure, and liver cancer. Given the high cost of treatment and the large number of HCV-infected individuals, identification of predictors of progressive liver disease and treatment outcome may aid in diagnosis and treatment planning on an individual patient basis. It has been shown that human microRNAs(miRNA) are needed to promote and maintain HCV infection. MicroRNAs are small ribonucleic acid (RNA) sequences which bind protein-producing RNA sequences, lowering concentrations of certain proteins in cells. There are many different miRNA sequences that are found in varying concentrations in the body; abnormal concentrations of certain miRNAs can be a symptom of viral disease. MicroRNAs can be packaged and delivered to cells in exosomes, small packaging bodies which are found in body fluids such as plasma. The purpose of this study is to identify exosomal miRNAs that vary in concentration in patients chronically infected with HCV pre-, during and post-treatment at different stages of HCV-associated liver disease progression. Exosomal miRNA from plasma samples from patients with chronic hepatitis C before, during, and at the end of HCV treatment will be isolated, quantified, and identified to determine the concentration of certain miRNA sequences associated with HCV infection. Outcome measures include the relationship between miRNA levels and the patients' stage of liver disease progression, the relationship in miRNA levels before, during and post- treatment, and the relationship in miRNA levels compared to responsiveness to the treatment by measured HCV load.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Noble, Jake W
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~